E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Diabetic foot syndrome with critical limb ischemia |
|
E.1.1.1 | Medical condition in easily understood language |
Non-healing wounds and loss of blood supply in the limbs of diabetic patients |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Metabolic Phenomena [G03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Lengthening of survival free of major amputation by a low dose therapy with Urokinase as a daily short infusion with 10 to 21 doses over max. 30 days within the scope of a randomized, controlled study |
|
E.2.2 | Secondary objectives of the trial |
• lengthening of survival free of major amputation one year after randomization
• major amputation
• overall mortality after 12 months
• minor amputation
• number of revision surgeries with minor amputations
• healing of the aim lesions (DFS)
• new lesions in the affected leg (index leg)
• new lesions in a previously not affected leg (not index leg)
• efficacy with dialysis patients
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients ≥ 18 years with diabetes and angiopathic or angioneuropathic diabetic foot syndrome with critical limb ischemia (at least Wagner-Armstrong stage 2C)
Additional inclusion criteria:
• No revascularization possible or rest ischemia after revascularization (ALP with
collateral curve, to post-stenosis curve or dumb curve or ABI <0.9 or Doppler
trace with character of stenosis or missing, TcPO2 <30 mmHg)
• Persistent ulcerations in spite of anti-biosis, blood glucose adjustment and
wound debridement
• Expected further in-patient stay of at least 3 weeks (antibiotic therapy as well as
decompression)
• Fibrinogen ≥ 4.0 g/ll
|
|
E.4 | Principal exclusion criteria |
• prospective life expectancy <1 year
• former major amputation
• treatment strategy major amputation after interdisciplinary treatment team
• pre-treatment of the current episode of the diabetic foot syndrome with Urokinase (permitted in connection with the revascularization with the distance to the randomization then being minimally 7 days)
• mechanical heart valve replacement
• cerebral event with CT-alteration within the last 3 months
• non-cured, proliferative retinopathy
• uncontrollable hypertension (syst. RR > 80 mmHg, diast. RR >100 mmHg
• hemorrhagic diathesis (spontaneous-Quick <50%, spontaneous-PTT > 40 s,
platelets <100 Gpt/l)
• gastrointestinal bleeding or ulcers during the last 4 weeks
• reverse bypass operation
• existence of other contra-indications for a Urokinase therapy according to the
current specialized information
• concurrent participation in another clinical study
• lacking compliance
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Lengthening of the survival free of major amputation in the Urokinase group in contrast to the group treated with standard therapy. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
12 months after randomization |
|
E.5.2 | Secondary end point(s) |
• lengthening of survival free of major amputation one year after randomization
• major amputation
• overall mortality after 12 months
• minor amputation
• number of revision surgeries with minor amputations
• healing of the aim lesions (DFS)
• new lesions in the affected leg (index leg)
• new lesions in a previously not affected leg (not index leg)
• efficacy with dialysis patients
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
12 months after randomization |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |